Start
•
Completion

Psilocybin Brain Stimulation and Imaging Pilot Study (OPTE)

Not yet recruitingRegisteredCTG

This open-label Phase I trial (n=15) will investigate the effects of psilocybin (25mg) on brain function and cognitive control in healthy adults, using electroencephalogram (EEG) and transcranial magnetic stimulation (TMS).

Details

Open-label, single-group Phase I pilot administering a single 25 mg oral dose of psilocybin to healthy volunteers (n=15) with concurrent TMS and EEG to probe neural and cognitive control effects.

Screening includes medical and psychiatric assessment, ECG and laboratory tests. Outcomes include EEG measures during TMS, cognitive control tasks, and safety/tolerability assessments.

Topics:Healthy Volunteers

Registry

Registry linkNCT06835699